PainPhase 3NCT00099203
A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease
A Phase 3 study testing ibandronate [Bondronat] and zoledronic acid in people with Pain and Bone Neoplasm, run by Hoffmann-La Roche at 72 sites in 18 countries.
Trial summary
This 2 arm study will compare the efficacy of intravenous Bondronat with that of zoledronic acid in patients with malignant bone disease experiencing moderate to severe pain. Patients will be randomized to receive either Bondronat (6mg iv on days 1, 2 and 3 and then every 3-4 weeks) or zoledronic acid (4mg iv on day 1… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pain, Bone Neoplasm, Neoplasm Metastasis
- What is being tested?
- ibandronate [Bondronat] and zoledronic acid
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 163 participants
- Where
- 72 sitesin 18 countries
- Study dates
- Jul 2005to Dec 2007
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- patients with malignant bone disease;
- patients with moderate to severe pain.
Who cannot join
- patients who have received a bisphosphonate within 3 weeks from the signing of the informed consent;
- patients receiving concurrent investigational therapy, or who have received investigational therapy within 30 days of the first scheduled day of dosing;
- untreated esophagitis or gastric ulcers;
- recent or pre-scheduled radiotherapy to bone;
- patients who are pregnant or breast-feeding.
Trial locations and contacts
72 sites in 18 countries.
72 sites in 18 countries
United States26 sites
Study site
Abilene, Texas, 79606-5208
Study site
Albany, New York, 12208
Study site
Arlington, Texas, 76014
Study site
Beaumont, Texas, 77702-1449
Study site
Birmingham, Alabama, 35205
Study site
Dallas, Texas, 75230
Study site
Dallas, Texas, 75231
Study site
Eugene, Oregon, 97401-8122
Study site
Fort Worth, Texas, 76177
Study site
Fredericksburg, Texas, 78624
Study site
Galesburg, Illinois, 61401
Study site
Henderson, Nevada, 89052
Study site
Indianapolis, Indiana, 46227
Study site
Kansas City, Missouri, 64131
Study site
Longview, Texas, 75601
Study site
Macon, Georgia, 31201
Study site
Nashville, Tennessee, 37209
Study site
Norfolk, Virginia, 23502
Study site
Ocoee, Florida, 34761
Study site
Oklahoma City, Oklahoma, 73120
Study site
Reno, Nevada, 89502
Study site
Round Rock, Texas, 78681
Study site
Seattle, Washington, 98104
Study site
Sedona, Arizona, 86336
Study site
Spokane, Washington, 99218
Study site
Vancouver, Washington, 98684
Russia8 sites
Study site
Kazan', 420029
Study site
Moscow, 115478
Study site
Moscow, 117837
Study site
Moscow, 125284
Study site
Moscow
Study site
Obninsk, 249020
Study site
Saint Petersburg, 197022
Study site
Saint Petersburg, 197758
Argentina6 sites
Study site
Buenos Aires, C1280AEB
Study site
Buenos Aires, C1406FWY
Study site
Buenos Aires, C1408INH
Study site
La Plata, 1900
Study site
Lanus, B1824DLR
Study site
Mendoza, 5500
Germany4 sites
Study site
Dessau, 06846
Study site
Duisburg, 47166
Study site
Heidelberg, 69120
Study site
Trier, 54290
Belgium3 sites
Study site
Brussels, 1000
Study site
Turnhout, 2300
Study site
Wilrijk, 2610
France3 sites
Study site
Lyon, 69373
Study site
Nice, 06189
Study site
Paris, 75248
Guatemala3 sites
Study site
Guatemala City, 01010
Study site
Guatemala City, 01015
Study site
Guatemala City
Mexico3 sites
Study site
Chihuahua City, 31000
Study site
Mérida, 97500
Study site
Mexico City, 03100
Poland3 sites
Study site
Lodz, 93-510
Study site
Olsztyn, 10-228
Study site
Otwock, 05-400
Puerto Rico2 sites
Study site
Ponce, 00733-1324
Study site
San Juan, 00921-3201
United Kingdom2 sites
Study site
Exeter, EX2 5DW
Study site
Wolverhampton, WV10 0QP
About this study
Official title: A Randomized, Placebo-controlled, Double-blind Study of the Effect of Bondronat Compared With Zoledronic Acid on Pain in Patients With Malignant Bone Disease Experiencing Moderate to Severe Pain
This 2 arm study will compare the efficacy of intravenous Bondronat with that of zoledronic acid in patients with malignant bone disease experiencing moderate to severe pain. Patients will be randomized to receive either Bondronat (6mg iv on days 1, 2 and 3 and then every 3-4 weeks) or zoledronic acid (4mg iv on day 1 and then every 3-4 weeks). The anticipated time of study treatment is 6-12 months, and the target sample size is 100-500 individuals.
- Conditions
- Pain, Bone Neoplasm, Neoplasm Metastasis
- Being tested
- ibandronate [Bondronat], zoledronic acid
- Medical subject headings
- Pain, Bone Neoplasms, Neoplasm Metastasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ibandronate [Bondronat]Drug
6mg iv on days 1-3, and every 3-4 weeks
zoledronic acidDrug
4mg iv on day 1 and every 3-4 weeks
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Not described Receives: Drug: ibandronate [Bondronat] |
| 2 | Active comparator | Not described Receives: Drug: zoledronic acid |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain, as measured by Brief Pain Inventory and analgesic use
Measured: Week 24
Secondary outcomes (4)
Performance score and QoL measures
Measured: Week 24
AEs and laboratory parameters
Measured: Throughout study
Opioid side effects
Measured: Throughout study
Skeletal-related events
Measured: Throughout study
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Dec 2004 (estimated)
- Study startJul 2005
- Primary completionDec 2007
- Study completionDec 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PainStudies of the same condition, open and under way.
- More trials run by Hoffmann-La RocheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Enrolment
- 163 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Clinical Trials, Study director, Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00099203
- Sponsor's protocol ID
- BO18040
- Status last verified
- Aug 2017
- First submitted
- 10 Dec 2004
- Last updated
- 16 Aug 2017
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Aug 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Placebo-controlled, Double-blind Study of the Effect of Bondronat Compared With Zoledronic Acid on Pain in Patients With Malignant Bone Disease Experiencing Moderate to Severe Pain
- ClinicalTrials.gov ID
- NCT00099203
- Acronym / sponsor ID
- BO18040
- Conditions
- Pain, Bone Neoplasm, Neoplasm Metastasis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Terminated
- Enrolment
- 163 participants (actual)
- Lead sponsor
- Hoffmann-La RocheIndustry (pharma, biotech, devices)
- Study start
- Jul 2005
- Primary completion
- Dec 2007 (actual)
- Study completion
- Dec 2007 (actual)
- First posted
- 10 Dec 2004 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This 2 arm study will compare the efficacy of intravenous Bondronat with that of zoledronic acid in patients with malignant bone disease experiencing moderate to severe pain. Patients will be randomized to receive either Bondronat (6mg iv on days 1, 2 and 3 and then every 3-4 weeks) or zoledronic acid (4mg iv on day 1 and then every 3-4 weeks). The anticipated time of study treatment is 6-12 months, and the target sample size is 100-500 individuals.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Drug: ibandronate [Bondronat] |
| 2 | Active comparator | Drug: zoledronic acid |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- patients with malignant bone disease;
- patients with moderate to severe pain.
Key exclusion criteria (5 listed)
- patients who have received a bisphosphonate within 3 weeks from the signing of the informed consent;
- patients receiving concurrent investigational therapy, or who have received investigational therapy within 30 days of the first scheduled day of dosing;
- untreated esophagitis or gastric ulcers;
- recent or pre-scheduled radiotherapy to bone;
- patients who are pregnant or breast-feeding.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ibandronate [Bondronat]6mg iv on days 1-3, and every 3-4 weeks | Drug | 1 |
| zoledronic acid4mg iv on day 1 and every 3-4 weeks | Drug | 2 |
Primary outcome
Pain, as measured by Brief Pain Inventory and analgesic use
Time frame: Week 24
4 secondary outcomes
Performance score and QoL measures
Time frame: Week 24
AEs and laboratory parameters
Time frame: Throughout study
Opioid side effects
Time frame: Throughout study
Skeletal-related events
Time frame: Throughout study
Results and safety
The study was stopped early. Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Aug 2017.
Related trials for Pain
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Recruiting
Empowered Relief® for Cancer Survivors With Chronic Pain
Chronic Pain Due to Cancer, Pain Catastrophizing
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Effects of Hip Hinge Exercises on Pain, Range of Motion and Functional Disability in Non-specific Low Back Pain.
Low Back Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Hoffmann-La Roche
72 sites in 18 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing ibandronate [Bondronat] and zoledronic acid in people with Pain and Bone Neoplasm, run by Hoffmann-La Roche at 72 sites in 18 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 16 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 72 sites in United States, Russia, Argentina, Germany, Belgium and 13 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early. Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain, as measured by Brief Pain Inventory and analgesic use (time frame: Week 24). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Aug 2017.